Non-steroidal anti-inflammatory drug use and markers of Parkinson's disease progression: A retrospective cohort study
- 4 October 2023
- journal article
- research article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 454, 120822
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research
This publication has 27 references indexed in Scilit:
- Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society‐unified Parkinson's disease rating scale scoresMovement Disorders, 2012
- Use of ibuprofen and risk of Parkinson diseaseNeurology, 2011
- Anti-inflammatory drugs and risk of Parkinson diseaseNeurology, 2010
- The role of DAT-SPECT in movement disordersJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Parkinson disease and risk of mortalityNeurology, 2008
- Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor‐αJournal of Neurochemistry, 2006
- Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialAnnals of Neurology, 2002
- Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest ReliabilityThe Clinical Neuropsychologist, 1998
- Education-Specific normative data on common neuropsy-chological indices for individuals older than 75 YearsThe Clinical Neuropsychologist, 1996
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989